Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reconstituting central nervous system niche cues partially restores homeostatic-like features in cultured murine primary microglia.

Scientific reports·2026
Same author

Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Paediatric Patients Who Did Not Receive Haematopoietic Stem Cell Transplantation: Case Reports of Patients From a German Academic Hospital.

EJHaem·2025
Same author

The phylogenetic age paradox of non-coding RNAs.

Leukemia research·2024
Same author

Use of nonacog beta pegol during surgery in persons with hemophilia B: a case series.

Research and practice in thrombosis and haemostasis·2023
Same author

Glycation Interferes with the Expression of Sialyltransferases and Leads to Increased Polysialylation in Glioblastoma Cells.

Cells·2023
Same author

Luciferase Expressing Preclinical Model Systems Representing the Different Molecular Subtypes of Colorectal Cancer.

Cancers·2023

Related Experiment Video

Updated: Mar 30, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.8K

Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells.

Dajana Reuter1, Martin S Staege1, Caspar D Kühnöl1

  • 1University Clinic and Polyclinic for Child and Adolescent Medicine, Martin Luther University Halle-Wittenberg , Halle , Germany.

Frontiers in Oncology
|November 19, 2015
PubMed
Summary

Interleukin-2 (IL-2) modified Ewing sarcoma cells show promise but need enhancement. Adding OX40 ligand (OX40L) to these cells may boost immune responses against Ewing sarcoma, improving immunotherapy strategies.

Keywords:
Ewing sarcomaOX40/OX40L systemco-stimulationimmunotherapytumor necrosis factor (receptor) superfamily

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.7K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

13.0K

Related Experiment Videos

Last Updated: Mar 30, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.8K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.7K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

13.0K

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Ewing sarcoma is a rare bone cancer.
  • Current Interleukin-2 (IL-2) therapies show limited efficacy in completely inhibiting tumor growth.
  • Co-stimulatory molecules are crucial for optimal T-cell activation in anti-tumor immunity.

Purpose of the Study:

  • To investigate the potential of OX40 ligand (OX40L) as a co-stimulatory molecule to enhance anti-tumor immune responses against Ewing sarcoma.
  • To generate and evaluate OX40L transgenic Ewing sarcoma cells for their immunostimulatory activity.

Main Methods:

  • Generation of OX40L transgenic Ewing sarcoma cells.
  • Assessment of preserved expression of Ewing sarcoma-associated antigens (e.g., EWSR1-FLI1 oncogene).
  • In vitro testing of immunostimulatory activity in combination with IL-2 and CD137 stimulation.

Main Results:

  • OX40L transgenic Ewing sarcoma cells maintained expression of key tumor antigens.
  • A trend towards enhanced immune stimulation against Ewing sarcoma was observed with OX40L expression.
  • Combined therapy with IL-2 and CD137 stimulation showed potential.

Conclusions:

  • The OX40/OX40L pathway holds potential for improving immunotherapy strategies for Ewing sarcoma.
  • Further research into co-stimulatory molecule integration may enhance treatment efficacy.